Baidu
map

Biomed Res Int:疾病的检测,外泌体或许比血浆更合适

2017-08-07 MedSci MedSci原创

MicroRNAs(miRNAs)是小的非编码RNA,参与调节了许多生物过程。既往研究表明人血浆中富含miRNA,血浆来源的外泌体可作为新的诊断标志物。本研究旨在确定血浆及血浆外泌体中miRNA的表达水平差异。研究人员采集了健康人群的血浆及血浆来源的外泌体,进行测序和定量分析,然后使用qRT-PCR在两组肺癌样本中验证其中3个miRNAs。结果显示,血浆与外泌体内仅有几个miRNAs的表达存在差异

MicroRNAs(miRNAs)是小的非编码RNA,参与调节了许多生物过程。既往研究表明人血浆中富含miRNA,血浆来源的外泌体可作为新的诊断标志物。本研究旨在确定血浆及血浆外泌体中miRNA的表达水平差异。

研究人员采集了健康人群的血浆及血浆来源的外泌体,进行测序和定量分析,然后使用qRT-PCR在两组肺癌样本中验证其中3个miRNAs。

结果显示,血浆与外泌体内仅有几个miRNAs的表达存在差异,而qRT-PCR进一步验证了大部分miRNAs并不存在一致性差异。然而,在肺癌样本中两种上调的miRNA(miR-181b-5P和miR–21-5P)在外泌体内的水平显著高于血浆中的水平。

该研究首次对比了健康人群中血浆miRNA与外泌体miRNA的差异。结果表明,二者的miRNA的水平相似,但是在肺癌患者中两种肿瘤相关的miRNA在外泌体中的水平显著高于血浆水平。

原始出处:

Fei Tian, Yanting Shen, et al., No Significant Difference between Plasma miRNAs and Plasma-Derived Exosomal miRNAs from Healthy People. Biomed Res Int. 2017; 2017: 1304816. Published online 2017 Jun 1. doi: 10.1155/2017/1304816.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917599, encodeId=9100191e5997e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 25 20:32:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607925, encodeId=c6cc160e92596, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 09 03:32:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231607, encodeId=f89b23160e3f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Aug 08 21:17:33 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231255, encodeId=af9e231255a6, content=不错的文章值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Aug 07 23:01:17 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231165, encodeId=4fae231165f3, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Mon Aug 07 15:19:28 CST 2017, time=2017-08-07, status=1, ipAttribution=)]
    2017-08-25 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1917599, encodeId=9100191e5997e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 25 20:32:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607925, encodeId=c6cc160e92596, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 09 03:32:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231607, encodeId=f89b23160e3f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Aug 08 21:17:33 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231255, encodeId=af9e231255a6, content=不错的文章值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Aug 07 23:01:17 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231165, encodeId=4fae231165f3, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Mon Aug 07 15:19:28 CST 2017, time=2017-08-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1917599, encodeId=9100191e5997e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 25 20:32:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607925, encodeId=c6cc160e92596, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 09 03:32:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231607, encodeId=f89b23160e3f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Aug 08 21:17:33 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231255, encodeId=af9e231255a6, content=不错的文章值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Aug 07 23:01:17 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231165, encodeId=4fae231165f3, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Mon Aug 07 15:19:28 CST 2017, time=2017-08-07, status=1, ipAttribution=)]
    2017-08-08 luominglian113

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1917599, encodeId=9100191e5997e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 25 20:32:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607925, encodeId=c6cc160e92596, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 09 03:32:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231607, encodeId=f89b23160e3f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Aug 08 21:17:33 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231255, encodeId=af9e231255a6, content=不错的文章值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Aug 07 23:01:17 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231165, encodeId=4fae231165f3, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Mon Aug 07 15:19:28 CST 2017, time=2017-08-07, status=1, ipAttribution=)]
    2017-08-07 131****2916

    不错的文章值得学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1917599, encodeId=9100191e5997e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 25 20:32:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607925, encodeId=c6cc160e92596, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 09 03:32:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231607, encodeId=f89b23160e3f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Aug 08 21:17:33 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231255, encodeId=af9e231255a6, content=不错的文章值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Aug 07 23:01:17 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231165, encodeId=4fae231165f3, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Mon Aug 07 15:19:28 CST 2017, time=2017-08-07, status=1, ipAttribution=)]
    2017-08-07 139****5926

    好好文章学习了

    0

相关资讯

Sci Rep:恶性细胞可通过外泌体传递其恶性特征促进癌症的进展

本研究旨在了解来自高转移细胞系的外泌体是否会影响侵略性较差癌细胞的行为以及血管内皮细胞的特性。结果发现,转移性结肠癌细胞能够通过外泌体将其转移表型传递给同源原代癌细胞,此种形态转变与侵袭性行为更强相关。此外,来源于转移细胞系的外泌体(SW620Exos)导致内皮通透性增高的能力较来源于非转移性细胞系外泌体的能力强(SW480Exos)。基于SWATH定量蛋白质组学分析显示,细胞骨架相关蛋白中SW6

Sci Rep:肿瘤来源的外泌体与中性粒细胞相互作用促进癌症相关血栓的形成

已知癌症患者患血栓栓塞性并发症的风险增加,目前研究人员提出了几种机制来解释肿瘤相关的血栓形成,包括肿瘤细胞外囊泡的释放和宿主血管细胞的活化。也有研究人员认为中性粒细胞外陷(NETs)有助于癌血栓的形成。在这项研究中,研究人员评估了肿瘤来源的外泌体和NETs在癌症相关血栓形成之间可能的合作关系。研究人员将4T1乳腺癌细胞原位注射到雌性BALB/c小鼠体内。荷瘤动物的血浆DNA和髓过氧化物酶的水平明显

J Extracell Vesicles:神经母细胞瘤来源的外泌体可通过MSCs促进致瘤因子的产生

骨髓(BM)龛是促进肿瘤细胞存活、休眠以及治疗性抵抗的微环境。发挥此功能的核心是间充质干细胞(MSCs)。研究人员使用神经母细胞瘤(NB)作为模型进行探究,结果表明,NB细胞释放富含蛋白质但缺乏细胞因子和趋化因子的细胞外囊(EVS)。研究人员使用三种不同的纯化方法,结果表明,Nb来源的外泌体可被MSCs捕捉并诱导致瘤性细胞因子和趋化因子的产生,包括白细胞介素-6(IL-6)、IL-8/CXCL8,

Sci Rep:血浆外泌体miR-125a-3p可作为早期结肠癌的诊断生物标志物

循环系统中外泌体在用于作为疾病的诊断和预后的生物标志物具有极大的潜力。本实验组既往研究中使用miRNA测序识别了异常表达的外泌体miRNA,将其作为结肠癌患者的候选诊断标志物。为验证此发现,本研究纳入了50名早期结肠癌患者和50名匹配的健康志愿者。分离其血浆来源的外泌体miRNA。实时定量PCR显示,早期结肠癌患者血浆外泌体的miR-125a-3p和miR-320c明显升高。ROC曲线显示,曲线下

Sci Rep:外泌体miRNAs的变化或可预测1型糖尿病的发生

1型糖尿病(T1DM)是自身免疫攻击胰岛素产生ß细胞而导致的慢性高血糖的结果。外泌体是来自细胞的膜状脂质囊泡,富含特异性miRNA,或可为某特定疾病的诊断提供信息。为了评估从外泌体中提取的miRNAs作为T1DM诊断的生物标志物的价值。研究人员利用差速离心分离出血浆中的外泌体,并通过纳米粒子跟踪分析和透射电子显微镜观察证实外泌体的存在。提取出外泌体内的总RNA,然后比较了12个T1DM患者和12个

PLoS One:通过外泌体分泌载体膜蛋白5促进α-突触核蛋白的分泌

自噬溶酶体途径是一种清除聚集蛋白和受损细胞器的细胞保护系统。同时,外泌体分泌是一种选择性的清除毒性蛋白的模式,如α-突触核蛋白。越来越多的证据表明,这两种细胞过程是协调的,以便于清除有毒的细胞废物;然而,这两种过程之间转换的调节器目前尚不清楚。本研究中,研究人员发现,SCAMP5——亨廷顿病患者的大脑中明显增多的一种分泌载体膜蛋白,可被蛋白压力和自噬刺激快速而短暂的诱导,是由主自噬转录调节因子TF

Baidu
map
Baidu
map
Baidu
map